Marker Therapeutics

20 articles about Marker Therapeutics

• Principal Investigator from City of Hope National Medical Center Invited to Present Clinical Data from Marker Therapeutics APOLLO Study at 11th Global Summit on Hematologic Malignancies 

  4/8/2024

  Marker Therapeutics, Inc. reported that Geoffrey Shouse, D.O., Ph.D., the Principal Investigator at City of Hope National Medical Center in Duarte, CA, was invited to present his clinical experience from the APOLLO study at the 11th Global Summit on Hematologic Malignancies in Whistler, BC, Canada.

• Marker Therapeutics Reports Year-End 2023 Corporate and Financial Results

  3/25/2024

  Marker Therapeutics, Inc. (Nasdaq: MRKR), a clinical-stage immuno-oncology company focusing on developing next-generation T cell-based immunotherapies for the treatment of hematological malignancies and solid tumors, today reported recent corporate developments and financial results for the year ended December 31, 2023.

• Marker Therapeutics to Present at the H.C. Wainwright 2nd Annual Cell Therapy Virtual Conference

  3/22/2024

  Marker Therapeutics, Inc. (Nasdaq: MRKR) today announced that Juan Vera, M.D., President and Chief Executive Officer of Marker Therapeutics, will present at the H.C. Wainwright 2nd Annual Cell Therapy Virtual Conference.

• Marker Therapeutics Receives Approval from United States Adopted Name (USAN) Council and International Nonproprietary Names (INN) Expert Committee for “Neldaleucel” as Nonproprietary Name for MT-601

  1/22/2024

  Marker Therapeutics, Inc. announced today that the United States Adopted Names (USAN) Council, and the World Health Organization (WHO) International Nonproprietary Names (INN) expert committee has approved “ neldaleucel ” as the nonproprietary (generic) name for MT-601, a multi-tumor associated antigen (multiTAA)-specific T cell product candidate for the treatment of patients with lymphoma.

• Marker Therapeutics Announces Clinical Program Updates and Pipeline Prioritization

  1/8/2024

  Marker Therapeutics, Inc. today announced a restructuring of its clinical programs and a strategic prioritization of its multi-tumor associated antigen (multiTAA)-specific T cell product pipeline.

• Marker Therapeutics Announces Participation in Biotech Showcase and the 19th Annual Non-Dilutive Funding Summit During “J.P. Morgan Week 2024”

  12/21/2023

  Marker Therapeutics, Inc. announced that the Company’s management team will participate in Biotech Showcase and present at the 19th Annual Non-Dilutive Funding Summit.

• Marker Therapeutics Announces Sustained Complete Response in First Lymphoma Patient Treated with MT-601 following CAR T Relapse

  12/11/2023

  Marker Therapeutics, Inc. today reported a clinical update on the APOLLO study.

• Marker Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Updates

  11/9/2023

  Marker Therapeutics, Inc. (Nasdaq: MRKR), a clinical-stage immuno-oncology company focusing on developing next-generation T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications, today reported corporate updates and financial results for the third quarter ended September 30, 2023.

• Marker Therapeutics Announces Complete Response in First Lymphoma Patient Treated with MT-601 after CAR T Relapse

  9/11/2023

  Marker Therapeutics, Inc. (Nasdaq: MRKR) is a clinical-stage immuno-oncology company focusing on developing next-generation T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications.

• Marker Therapeutics to Present at the H.C. Wainwright 25th Annual Global Investment Conference

  8/30/2023

  Marker Therapeutics, Inc. (Nasdaq: MRKR) today announced that Juan F. Vera, M.D., President and Chief Executive Officer, will present at the H.C. Wainwright 25th Annual Global Investment Conference, which is being held on September 11-13, 2023 at the Lotte New York Palace Hotel in New York City.

• Marker Therapeutics Reports Second Quarter 2023 Financial Results and Provides Business Update

  8/14/2023

  Marker Therapeutics, Inc. (Nasdaq: MRKR), a clinical-stage immuno-oncology company focusing on developing next-generation T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications, today reported corporate updates and financial results for the second quarter ended June 30, 2023.

• Marker Therapeutics Reports Non-Clinical Proof-of-Concept Data and Update on Clinical Readiness for the MT-401 Off-the-Shelf Program

  8/7/2023

  Marker Therapeutics, Inc. today announced non-clinical data of its lead multi-tumor-associated antigen (multiTAA)-specific T cell product candidate, MT-401, in an Off-the-Shelf (OTS) setting and provided an update on clinical readiness for the OTS program.

• Marker Therapeutics to Participate in Virtual Roundtable with Key Opinion Leaders to Discuss Clinical Landscape of CAR-T Cell Therapies on August 9, 2023

  7/26/2023

  Marker Therapeutics, Inc. today announced participation in a live webcast produced by Demy-Colton and sponsored by the WBB Research Institute titled “Beyond CAR-T, What’s Next for Cell Therapy”.

• European Medicines Agency Grants Orphan Drug Designation for MT-401 developed by Marker Therapeutics for the Treatment of AML Patients

  7/10/2023

  Marker Therapeutics, Inc. (Nasdaq: MRKR) announced that zedenoleucel, its multi-tumor-associated antigen (multiTAA)-specific T cell product candidate, MT-401, was granted Orphan Drug Designation by the Committee for Orphan Medicinal Products of the European Medicines Agency (EMA) for the treatment of patients with acute myeloid leukemia (AML).

• Marker Therapeutics Reports MT-401 Non-Clinical Data in AML Cells after Hypomethylating Agent Administration

  6/26/2023

  Marker Therapeutics, Inc. today reports non-clinical data on its lead multi-tumor-associated antigen (multiTAA)-specific T cell product candidate, MT-401, which showed increased anti-tumor activity against an acute myeloid leukemia (AML) cell line after treatment with hypomethylating agents (HMA).

• Marker Therapeutics Announces First Lymphoma Patient Treated with MT-601 in Phase 1 Clinical Trial

  6/12/2023

  Marker Therapeutics, Inc. announced that the first patient has been treated in the company sponsored Phase 1 multicenter APOLLO trial investigating MT-601, a multi-tumor-associated antigen -specific T cell product targeting six antigens, for the treatment of patients with lymphoma who have failed or are ineligible to receive anti-CD19 CAR T cell treatment.

• Marker Therapeutics Reports Pre-Clinical Data of its MT-601 MultiTAA-Specific T Cell Product Candidate in Lymphoma CellsMT-601 showed anti-tumor activity against CD19 CAR T refractory lymphoma cells in vitro

  5/31/2023

  Marker Therapeutics, Inc. announced pre-clinical data from the Company’s multiple tumor-associated antigens -specific T cell product candidate MT-601 in lymphoma cells, including CD19 CAR T refractory cells.

• Marker Therapeutics Appoints Monic Stuart, M.D., as Chief Medical Officer

  5/8/2023

  Marker Therapeutics, Inc. today announced the appointment of Monic Stuart, M.D., as its new Chief Medical Officer.

• Marker Therapeutics Announces Comprehensive Non-Dilutive Agreement With CellReady™

  5/1/2023

  Marker Therapeutics, Inc. today announced that it has entered into a comprehensive agreement with CellReady™, a newly formed Contract Development and Manufacturing Organization (CDMO) founded by John Wilson, founder and CEO of Wilson Wolf Corporation and Marker Co-Founder and Board Member.

• Marker Therapeutics Reports Fiscal Year 2022 Corporate and Financial Results

  3/22/2023

  Marker Therapeutics, Inc. today reported fiscal year 2022 financial results and provided updates for its clinical development programs.